The odontogenic ameloblast‐associated protein (ODAM) cooperates with RUNX2 and modulates enamel mineralization via regulation of MMP‐20

We have previously reported that the odontogenic ameloblast‐associated protein (ODAM) plays important roles in enamel mineralization through the regulation of matrix metalloproteinase‐20 (MMP‐20). However, the precise function of ODAM in MMP‐20 regulation remains largely unknown. The aim of the present study was to uncover the molecular mechanisms responsible for MMP‐20 regulation. The subcellular localization of ODAM varies in a stage‐specific fashion during ameloblast differentiation. During the secretory stage of amelogenesis ODAM was localized to both the nucleus and cytoplasm of ameloblasts. However, during the maturation stage of amelogenesis, ODAM was observed in the cytoplasm and at the interface between ameloblasts and the enamel layer, but not in the nucleus. Secreted ODAM was detected in the conditioned medium of ameloblast‐lineage cell line (ALC) from days 14 to 21, which coincided with the maturation stage of amelogenesis. Interestingly, the expression of Runx2 and nuclear ODAM correlated with MMP‐20 expression in ALC. We therefore examined whether ODAM cooperates with Runx2 to regulate MMP‐20 and modulate enamel mineralization. Increased expression of ODAM and Runx2 augmented MMP‐20 expression, and Runx2 expression enhanced expression of ODAM, although overexpression of ODAM did not influence Runx2 expression. Conversely, loss of Runx2 in ALC decreased ODAM expression, resulting in down‐regulation of MMP‐20 expression. Increased MMP‐20 expression accelerated amelogenin processing during enamel mineralization. Our data suggest that Runx2 regulates the expression of ODAM and that nuclear ODAM serves an important regulatory function in the mineralization of enamel through the regulation of MMP‐20 apart from a different, currently unidentified, function of extracellular ODAM. J. Cell. Biochem. 111: 755–767, 2010. © 2010 Wiley‐Liss, Inc.     

Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin

Lytic bacteriophages (phages) have been investigated as treatments for bacterial infectious diseases. An induced phage, SAP-26, was isolated from a clinical isolate of Staphylococcus aureus. It belongs to the family Siphoviridae and its genome consists of double-stranded 41,207 bp DNA coding for 63 open reading frames. The phage SAP-26 showed a wide spectrum of lytic activity against both methicillin-resistant S. aureus and methicillin-susceptible S.aureus. Furthermore, combined treatment with a phage and antimicrobial agents showed a strong biofilm removal effect which induced structural changes in the biofilm matrix and a substantial decrease in the number of bacteria. Such a broad host range in S. aureus and biofilm removal activity of the phage SAP-26 suggests the possibility of its use as a therapeutic phage in combination with appropriate antimicrobial agent(s). Among the three antimicrobial agents combined with phage, the combination of rifampicin showed the best biofilm removal effect. To the authors' knowledge, this study showed for the first time that S. aureus biofilm could be efficiently eradicated with the mixture of phage and an antimicrobial agent, especially rifampicin.     

Acanthamoeba: could it be an environmental host of Shigella?

Shigellosis is a serious public health problem in Korea, because large outbreaks of Shigella sonnei infections were recorded in many parts of the country during the period 1998-2000. However, the epidemiological features of shigellosis are not well known. In this study, we devised conditions suitable for the growth and replication of Shigella in an amoebic intracellular environment, and investigate whether medium conditions affect the survival and replication of Shigella within Acanthamoeba. We evaluated the uptake rates of invasive and non invasive S. sonnei strains by three Acanthamoeba species, namely, A. castellanii Neff, A. astronyxis Ray & Hayes, and A. healyi OC-3A. When A. castellanii Neff was infected with S. sonnei 99OBS1 or 80DH248, shigellae was maintained for a longer time in cytoplasms than in other Acanthamoeba species. S. sonnei 99OBS1 strain (a virulent strain) was recovered in higher numbers than the non-virulent S. sonnei 80DH248 strain in all experiments. Moreover, S. sonnei was more easily engulfed by Acanthamoeba at 18 degrees C. The shigellae uptake rates of Neff strain, which was cultured in free-media (less nutrition), were higher (>10-fold) than those observed in original amoeba culture media (PYG medium) in all time points. S. sonnei 99OBS1 was localized, with an intact membrane, to the vacuoles of Acanthamoeba. We conclude that free-living amoebae more likely act as environmental hosts for shigellae, and thus, may have contributed to outbreaks of shigellosis in Korea.     

Kif3a interacts with Dynactin subunit p150Glued to organize centriole subdistal appendages

Formation of cilia, microtubule‐based structures that function in propulsion and sensation, requires Kif3a, a subunit of Kinesin II essential for intraflagellar transport (IFT). We have found that, Kif3a is also required to organize centrioles. In the absence of Kif3a, the subdistal appendages of centrioles are disorganized and lack p150^Glued and Ninein. Consequently, microtubule anchoring, centriole cohesion and basal foot formation are abrogated by loss of Kif3a. Kif3a localizes to the mother centriole and interacts with the Dynactin subunit p150^Glued. Depletion of p150^Glued phenocopies the effects of loss of Kif3a, indicating that Kif3a recruitment of p150^Glued is critical for subdistal appendage formation. The transport functions of Kif3a are dispensable for subdistal appendage organization as mutant forms of Kif3a lacking motor activity or the motor domain can restore p150^Glued localization. Comparison to cells lacking Ift88 reveals that the centriolar functions of Kif3a are independent of IFT. Thus, in addition to its ciliogenic roles, Kif3a recruits p150^Glued to the subdistal appendages of mother centrioles, critical for centrosomes to function as microtubule‐organizing centres.     

Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency

Cell reprogramming technology has allowed the in vitro control of cell fate transition, thus allowing for the generation of highly desired cell types to recapitulate in vivo developmental processes and architectures. However, the precise molecular mechanisms underlying the reprogramming process remain to be defined. Here, we show that depleting p53 and p21, which are barriers to reprogramming, yields a high reprogramming efficiency. Deletion of these factors results in a distinct mitochondrial background with low expression of oxidative phosphorylation subunits and mitochondrial fusion proteins, including mitofusin 1 and 2 (Mfn1/2). Importantly, Mfn1/2 depletion reciprocally inhibits the p53-p21 pathway and promotes both the conversion of somatic cells to a pluripotent state and the maintenance of pluripotency. Mfn1/2 depletion facilitates the glycolytic metabolic transition through the activation of the Ras-Raf and hypoxia-inducible factor 1α (HIF1α) signaling at an early stage of reprogramming. HIF1α is required for increased glycolysis and reprogramming by Mfn1/2 depletion. Taken together, these results demonstrate that Mfn1/2 constitutes a new barrier to reprogramming, and that Mfn1/2 ablation facilitates the induction of pluripotency through the restructuring of mitochondrial dynamics and bioenergetics.Cell fate transition occurs under various developmental, physiological, and pathological conditions, including normal embryonic development, aging, and tissue regeneration, as well as tumor initiation and progression. Defining the cellular and molecular mechanisms of cell fate transition and learning to control these mechanisms may be essential for treating abnormal pathological conditions resulting from improper regulation of cell fate. The recent development of induced pluripotent stem cell (iPSC) technology has allowed for the reprogramming of somatic cells to pluripotent stem cells through the use of defined pluripotency factors, and has allowed us to more closely mimic and recapitulate the conditions of cell fate transitions.¹ In studying aspects of somatic cell reprogramming related to pluripotency, dramatic and complex molecular changes at the genetic, epigenetic, and metabolic levels have been observed during the initial stage of reprogramming.² Cell reprogramming faces the challenge of balancing stability and plasticity and must overcome critical barriers, such as cell cycle checkpoints, the mesenchymal–epithelial transition, and metabolic reprogramming, to progress cell fate conversion from a stochastic early phase toward pluripotency.³The p53 pathway limits cell fate transition by inducing classical signaling that leads to cell cycle arrest, senescence, or apoptosis to maintain genome stability in the face of reprogramming-induced stress. Thus, compromising p53 signaling accelerates the reprogramming process.^{4, 5, 6} Recent reports have provided data showing that the fast-cycling population is enriched in p53 knockdown cells, which secures the transition to pluripotency.⁷ It has also been observed that p53 induces the differentiation of damaged embryonic stem cells (ESCs) by suppressing the pluripotency factors, Nanog and Oct4.⁸ Moreover, p53 governs cellular state homeostasis, which constrains the mesenchymal–epithelial transition by inhibiting Klf4-mediated expression of epithelial genes early in the reprogramming process,⁹ and opposes glycolytic metabolic reprogramming, thereby playing an oncosuppressive role.¹⁰ Through the regulation of these canonical and emergent functions, p53 maintains cellular integrity and stability under conditions of cell fate transition.Highly proliferative cells, such as iPSCs and tumor cells, prefer to undergo glycolysis and decrease their dependency on mitochondrial ATP production, which requires the biosynthesis of macromolecules and the alleviation of mitochondrial oxidative stress in rapidly growing cells.¹¹ Furthermore, there are substantial mitochondrial structural changes that interconnected mitochondrial network of somatic cells transforms into an immature phenotype during metabolic reprogramming.¹² These morphological and functional changes in mitochondria are controlled by fusion and fission processes, which are primarily mediated by the dynamin-related GTPases, mitofusins (Mfn) and dynamin-related protein 1 (Drp1), respectively.¹³ Our previous data demonstrated that Drp1 activation via the pluripotency factor Rex1 promotes mitochondrial fragmentation, which contributes to the acquisition and maintenance of stem cell pluripotency.¹⁴ Balancing mitochondrial dynamics is crucial for maintaining cellular homeostasis, and an abnormal mitochondrial dynamic can result in numerous diseases. However, the relevant roles of mitochondrial structural proteins in the cell fate conversion process are not completely understood.Here, we decipher an early stage of cellular reprogramming in a p53 knockout (KO) context related to its function as a cell fate transition checkpoint. p53- and p21-KO cells express low levels of Mfn1/2 at an early stage of reprogramming, and restructuring mitochondrial dynamics and bioenergetics by ablating Mfn promotes the conversion of these cells to a pluripotent cell fate. Our work reveals novel roles of the mitochondrial fusion proteins Mfn1/2 driving entry to and exit from pluripotency by the coordinated integration of p53 signaling.     

NABIC SNP: an integrated database for SNP markers

AvailabilityThe database is available online for free at http://nabic.rda.go.kr/SNP     

Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease

Genetic mutation of α-synuclein (α-SYN) is clearly verified as the causal factor of human and mouse Parkinson's disease. However, biological function of α-SYN has not been clearly demonstrated until now. In this investigation, we reveal that α-SYN is a co-regulator of growth factor-induced AKT activation. Elimination of SYN reduces the IGF-1-mediated AKT activation. Similarly, mutant SYN suppresses the IGF-1-induced AKT activation. Wild-type SYN can interact with AKT and enhance the solubility and plasma localization of AKT in response to IGF-1, whereas mutant α-SYNs do not interact with AKT. In addition, elevated expression of SYN blocks the AKT activation. We also find that si-RNA against α-SYN abolished the protective effect of IGF-1 against DNA damage-induced apoptosis. Our result strongly indicates that Parkinson's disease, induced by α-SYN mutation, is evoked by deregulation of the AKT-signaling cascade.